CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,488 enrolled
Drug / intervention
FMX101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03271021
NCT03271021Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)

Vyne Therapeutics Inc.·interventional·Posted Sep 1, 2017·Updated Jan 18, 2022

In Brief

A Phase 3 clinical trial evaluating FMX101 and Vehicle Foam for Acne Vulgaris. Completed, enrolled 1,488 participants across 98 sites.

Detailed Summary

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedSep 1, 2017
Enrollment StartJul 17, 2017
Primary CompletionSep 4, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.8 years ago

Interventions

FMX101drug

FMX101, 4% minocycline foam

Vehicle Foamdrug

Vehicle Foam